AZN Projected Dividend Yield
ADR (Sponsored)/AstraZeneca Plc ( NASDAQ : AZN )AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. 30 YEAR PERFORMANCE RESULTS |
AZN Dividend History Detail AZN Dividend News AZN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2024 |
N/A |
Aug 09, 2024 |
Aug 09, 2024 |
Sep 09, 2024 |
0.4900 |
2024 |
N/A |
Feb 22, 2024 |
Feb 23, 2024 |
Mar 25, 2024 |
0.9650 |
2024 Total: |
1.4550 |
||||
2023 |
N/A |
Aug 10, 2023 |
Aug 11, 2023 |
Sep 11, 2023 |
0.4550 |
2023 |
N/A |
Feb 23, 2023 |
Feb 24, 2023 |
Mar 27, 2023 |
0.9650 |
2023 Total: |
1.4200 |
||||
2022 |
N/A |
Aug 11, 2022 |
Aug 12, 2022 |
Sep 12, 2022 |
0.4550 |
2022 |
N/A |
Feb 24, 2022 |
Feb 25, 2022 |
Mar 28, 2022 |
0.9650 |
2022 Total: |
1.4200 |
||||
2021 |
N/A |
Aug 12, 2021 |
Aug 13, 2021 |
Sep 13, 2021 |
0.4400 |
2021 |
N/A |
Feb 25, 2021 |
Feb 26, 2021 |
Mar 29, 2021 |
0.9300 |
2021 Total: |
1.3700 |
||||
2020 |
N/A |
Aug 13, 2020 |
Aug 14, 2020 |
Sep 14, 2020 |
0.4400 |
2020 |
N/A |
Feb 27, 2020 |
Feb 28, 2020 |
Mar 30, 2020 |
0.9300 |
2020 Total: |
1.3700 |